 murin monoclon antibodi therapi patient plasma cell leukemia patient primari plasma cell leukemia resist chemotherapi month daili intraven inject monoclon antibodi moab patient clinic statu treatment major side effect serial monitor blockag myeloma cell prolifer bone marrow myeloma cell s-phase vivo reduct serum calcium serum monoclon igg serum c-reactiv protein level serum calcium serum monoclon igg c-reactiv protein undetect level treatment major side effect platelet neutrophil count therapi transient immun day initi treatment recoveri myeloma cell prolifer month treatment myeloma cell phase conclus first clinic trial feasibl moab transient tumor cytostasi reduct toxic major biolog activ vivo basi develop therapi myeloma diseas